

04-21-01

046
4-901

#8
Plunkett
12/14/01

This correspondence is being sent via Express Mail
No. EL576314630US to, Assistant Commissioner for Patents,
Washington, D.C. 20231 on April 10, 2001.

APR 10 2001
PATENT AND TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

US Serial No.:	09/723,307	}	Examiner:	Unknown
Filing Date:	November 27, 2000	}	Group Art	
Inventor(s):	CALENOFF et al.	}	Number:	Unknown
Title:	IMMUNOGENIC CANCER	}		
	PEPTIDES AND USES	}		
	THEREOF	}		
Attorney Docket:	21417/91482	}		

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement constitutes a bona fide attempt to comply with 37 C.F.R. §1.97(b) and §1.98. A copy of each reference cited herein is provided for review by the Examiner. Pursuant to 37 C.F.R. § 1.56, this Statement is filed in the application identified above.

No representation is intended that a complete search has been made of the prior art. The filing of this Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in §1.56(b).

PUBLICATIONS**U.S. PATENTS**

<u>Document Number</u>	<u>Issued</u>	<u>Inventor(s)</u>
4,399,216	Aug. 16, 1983	Axel, et al.
4,585,742	Apr. 29, 1986	Bernal
5,194,254	Mar. 16, 1993	Barber, et al.
5,342,774	Aug. 30, 1994	Boon, et al.
5,593,972	Jan. 14, 1997	Weiner, et al.
5,616,477	Apr. 1, 1997	Price
5,620,955	Apr. 15, 1997	Knight, et al.
5,736,517	Apr. 7, 1998	Bogden, et al.
5,750,110	May 12, 1998	Prieels, et al.
5,763,164	June 9, 1998	Calenoff
5,770,721	June 23, 1998	Ershov, et al.
5,772,997	June 30, 1998	Hudziak, et al.
5,817,637	Oct. 6, 1998	Weiner, et al.
5,830,876	Nov. 3, 1998	Weiner, et al.
5,837,251	Nov. 17, 1998	Srivastava
5,851,756	Dec. 22, 1998	Steinman, et al.
5,861,247	Jan. 19, 1999	Mirzabekov, et al.
5,871,756	Feb. 16, 1999	Jeffcoat, et al.

5,876,735	Mar. 2, 1999	Reed
5,876,966	Mar. 2, 1999	Reed
5,942,235	Aug. 24, 1999	Paoletti
5,962,320	Oct. 5, 1999	Robinson
5,981,505	Nov. 9, 1999	Weiner, et al.
5,981,706	Nov. 9, 1999	Wallen, et al.
5,985,270	Nov. 16, 1999	Srivastava
5,997,873	Dec. 7, 1999	Srivastava
6,013,268	Jan. 11, 2000	Reed
6,030,618	Feb. 29, 2000	Srivastava
6,051,237	Apr. 18, 2000	Paterson
6,063,384	May 16, 2000	Morrow, et al.
6,077,663	June 20, 2000	Curiel, et al.
6,080,399	June 27, 2000	Gajewski, et al.
6,080,409	June 27, 2000	Laus, et al.
6,106,829	Aug. 22, 2000	He, et al.
6,136,315	Oct. 24, 2000	Srivastava

OTHER DOCUMENTS

- BARRATT-BOYES, S.M., *et al.* (1998) "Chimpanzee Dendritic Cells Derived In Vitro from Blood Monocytes and Pulsed with Antigen Elicit Specific Immune Responses In Vivo." Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Antigen Processing and Presentation. *J. Immunother.* 21(2): 142-148.
- BEGUM, N.A. *et al.* (1995) "Differential Display and Integrin Alpha 6 Messenger RNA Overexpression in Hepatocellular Carcinoma." *Hepatology.* 22(5): 1447-1455.
- BONKHOF, H. (1998) "Analytical Molecular Pathology of Epithelial-Stromal Interactions in the Normal and Neoplastic Prostate." *Anal. Quant. Cytol. Histol.* 20(5): 437-442.
- BRAME, C.J. *et al.* (1999) "Identification of Extremely Reactive γ -Ketoaldehydes (Isolevuglandins) as Products of the Isoprostane Pathway and Characterization of Their Lysyl Protein Adducts." *J. Biol. Chem.* 274(19): 13139-13146.
- BRYDEN, A.A.G., *et al.* (1999) "Paradoxical Expression of E-Cadherin in Prostatic Bone Metastases." *BJU Int.* 84(9): 1032-1034.
- CHEEVER, M.A., *et al.* (1997) "Therapy with Cultured T Cells: Principles Revisited." *Immunol Rev.* 157: 177-194.
- CRESS, A.E., *et al.* (1995) "The $\alpha 6 \beta 1$ and $\alpha 6 \beta 4$ Integrins in Human Prostate Cancer Progression." *Cancer Metastasis Revs.* 14(3): 219-228.
- DAMIANO, J.S. *et al.* (1999) "Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines." *Blood* 93(5): 1658-1667.
- DAMJANOVICH, L. *et al.* (1997) "Integrin Expression on Normal and Neoplastic Human Breast Epithelium." *Acta Chir. Hung.* 36(1-4): 69-71.
- DISIS, M.L. *et al.* (1999) "Generation of Immunity to the HER-2/*neu* Oncogenic Protein in Patients with Breast and Ovarian Cancer using a Peptide-based Vaccine." *Clin. Cancer Res.* 5(6): 1289-1297.
- DISIS, M.L., *et al.* (1997) "HER-2/*neu* Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer." *Advances in Cancer Research* 344-370.

- DISIS, M.L. *et al.* (1998) "HER-2/neu Oncogenic Protein: Issues in Vaccine Development." *Crit. Revs. Immunol.* 18(1-2): 37-45.
- DISIS, M.L. *et al.* (1998) "Human HER-2/neu Protein Immunization Circumvents Tolerance to Rat neu: A Vaccine Strategy for "Self" Tumour Antigens." *Immunology* 93(2): 192-199.
- DONG, J-T., *et al.* (1996) "Down-Regulation of the *KAI1* Metastasis Suppressor Gene during the Progression of Human Prostatic Cancer Infrequently Involves Gene Mutation or Allelic Loss." *Cancer Res.* 56(19): 4387-4390.
- EKBLOM, M., *et al.* (1998) "Laminin Isoforms and Epithelial Development." *Ann. N.Y. Acad. Sci.* 857: 194-211.
- FAUCHÈRE, J.L. *et al.* (1983) "Hydrophobic Parameters II of Amino-Acid Side Chains from the Partitioning of N-Acetyl-Amino-Acid Amides." *Eur. J. Med. Chem.* 18(4): 369-375.
- FLEISCHMAJER, R. *et al.* (1998) "There is Binding of Collagen IV to $\beta 1$ Integrin during Early Skin Basement Membrane Assembly." *Ann. N.Y. Acad. Sci.* 857: 212-227.
- FRAGA, S., *et al.* (1990) "Prediction of the Secondary Structure and Functional Sites of Major Histocompatibility Complex Molecules." *J. Mol. Recognit.* 3(2): 65-73.
- FRIEDL, P., *et al.* (1998) "Integrins, Cell Matrix Interactions and Cell Migration Strategies: Fundamental Differences in Leukocytes and Tumor Cells." *Cell Adhes. Commun.* 6(2-3): 225-236.
- FUDGE, K., *et al.* (1994) "Immunohistochemistry Analysis of Platelet-derived Growth Factor A and B Chains and Platelet-derived Growth Factor α and β Receptor Expression in Benign Prostatic Hyperplasias and Gleason-graded Human Prostate Adenocarcinomas." *Mod. Pathol.* 7(5): 549-554.
- FUJIWARA, H. (1998) "Physiological Roles of Integrin $\alpha_6 \beta_1$ in Ovarian Functions." *Harm. Res.* 50(2): 25-29.
- FURUKAWA, F., *et al.* (1994) "Cadherins in Cutaneous Biology." *J. Dermatol.* 21(11): 802-813.
- GILEWSKI, T., *et al.* (2000) "Vaccination of High-Risk Breast Cancer Patients with Mucin-1 (MUC1) Keyhole Limpet Hemocyanin Conjugate plus QS-21¹." *Clin. Cancer Res.* 6(5): 1693-1701.
- GIRI, D., *et al.* (1999) "Alterations in Expression of Basic Fibroblast Growth Factor (FGF) 2 and its Receptor FGFR-1 in Human Prostate Cancer¹." *Clin. Cancer Res.* 5(5): 1063-1071.

- GOLDENBERG, D.M. (1993) "Monoclonal Antibodies in Cancer Detection and Therapy." *Am. J. Med.* 94(3): 297-312.
- GRASSO, A.W., *et al.* (1997) "ErbB Kinases and NDF Signaling in Human Prostate Cancer Cells." *Oncogene* 15(22): 2705-2716.
- HENDERSON, R.A., *et al.* (1998) "Retroviral Expression of MUC-1 Human Tumor Antigen with Intact Repeat Structure and Capacity to Elicit Immunity In Vivo." Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer. Tumor Antigens Recognized by T Cells. *J. Immunother.* 21(4): 247-256.
- HOPP, T.P. *et al.* (1981) "Prediction of Protein Antigenic Determinants from Amino Acid Sequences." *Proc. Natl. Acad. Sci. USA.* 78(6): 3824-3828.
- HUDZIAK, R.M., *et al.* (1989) "p185^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor." *Mol. Cell. Biol.* 9(3): 1165-1172.
- HUSSAIN, R., *et al.* (1996) "Structure-Function Correlation and Biostability of Antibody CDR-Derived Peptides as Tumour Imaging Agents." *Biomed. Pept. Proteins Nucleic Acids* 2(3): 67-70.
- KATSURA, M. *et al.* (1998) "Overexpression of CD44 Variants 6 and 7 in Human Endometrial Cancer." *Gynecol. Oncol.* 71(2): 185-189.
- KRAMER, G., *et al.* (1995) "High Expression of A CD38-Like Molecule in Normal Prostatic Epithelium and its Differential Loss in Benign and Malignant Disease." *J. Urol.* 154(5): 1636-1641.
- LOHI, J., *et al.* (1998) "Neoexpression of the Epithelial Adhesion Complex Antigens in Thyroid Tumours is Associated with Proliferation and Squamous Differentiation Markers." *J. Pathol.* 184(2): 191-196.
- PARKER, J.M.R., *et al.* (1986) "New Hydrophilicity Scale Derived from High-Performance Liquid Chromatography Peptide Retention Data: Correlation of Predicted Surface Residues with Antigenicity and X-ray-Derived Accessible Sites." *Biochemistry* 25: 5425-5432.
- RABINOVITZ, I., *et al.* (1995) "Integrin $\alpha 6$ Expression in Human Prostate Carcinoma Cells is Associated with a Migratory and Invasive Phenotype *in vitro* and *in vivo*." *Clin. Exp. Metastasis* 13(6): 481-491.
- ROKHLIN, O.W., *et al.* (1997) "Fas-mediated Apoptosis in Human Prostatic Carcinoma Cell Lines." *Cancer Res.* 57(9): 1758-1768.

- ROMANOV, V.I., *et al.* (1999) "RGD-Recognizing Integrins Mediate Interactions of Human Prostate Carcinoma Cells with Endothelial Cells In Vitro." *Prostate* 39(2): 108-118.
- RUOSLAHTI, E. (1997) "Integrins as Signaling Molecules and Targets for Tumor Therapy." *Kidney Int.* 51(5): 1413-1417.
- SHAMSI, F.A., *et al.* (1998) "Immunological Evidence for Methylglyoxal-derived Modifications *in Vivo*." *J. of Biol. Chem.* 273(12): 6928-6936.
- SHAMSI, K., *et al.* (1998) "Superparamagnetic Iron Oxide Particles (SH U 555 A): Evaluation of Efficacy in Three Doses for Hepatic MR Imaging." *Radiology* 206(2): 365-371.
- SUZUKI, K. *et al.* (1999) "Reduced Substratum Adhesion and Decreased Expressions of $\beta 1$ and $\beta 4$ Integrins in Human Breast Cancer Cells with a Property of Anchorage-Independent Growth." *Int. J. Oncol.* 14(5): 897-904.
- TAKAHASHI, S., *et al.* (1998) "Relationship between CD44 Expression and Differentiation of Human Prostate Adenocarcinomas." *Cancer Letts.* 129(1): 97-102.
- TO, S.Y.C., *et al.* (1992) "Monoclonal Antibody-Coated Magnetite Particles as Contrast Agents for MR Imaging and Laser Therapy of Human Tumors." *J. Clin. Laser Med. Surg.* 10(3): 159-169.
- TOZAWA, K. (1996) "Activation of Nuclear Factor- κ B and Control of the Expression of Cell Adhesion Molecules in Human Prostate Cancer Cells." *Nippon Hinyokika Gakkai Zasshi* 87(9): 1082-1091.
- TSIMIKAS, S., *et al.* (1999) "Radiolabeled MDA2, an Oxidation-Specific, Monoclonal Antibody, Identifies Native Atherosclerotic Lesions *in Vivo*." *J. Nucl. Cardiol.* 6(1): 41-53.
- WATANABE, M., *et al.* (1999) "Progression-linked Overexpression of c-Met in Prostatic Intraepithelial Neoplasia and Latent as well as Clinical Prostate Cancers." *Cancer Letts.* 141(1-2): 173-178.
- ZHENG, Duo-Qi, *et al.* (1999) "Prostatic Carcinoma Cell Migration via $\alpha_v\beta_3$ Integrin Is Modulated by a Focal Adhesion Kinase Pathway¹." *Cancer Res.* 59(7): 1655-1664.

None of the cited documents are believed to disclose or suggest the invention recited in the claims of the above-identified application. It is therefore believed that the claimed invention is patentably distinguishable over these documents.

The person making this Statement is the attorney who signs below on the basis of the information in the attorney's file and as provided by Applicant and his representatives.

Please charge any fees that might be due in connection with this Information Disclosure Statement to our Deposit Account No. 10-0435.

Respectfully submitted,

BARNES & THORNBURG

A handwritten signature in cursive script, appearing to read "Alice O. Martin".

Alice O. Martin

Attorney Registration No. 35,601

Barnes & Thornburg
2600 Chase Plaza
10 South LaSalle Street
Chicago, IL 60603
(312) 357-1313
April 9, 2001